Pharmacokinetics of parenteral and oral melperone in man


The pharmacokinetics of melperone (Buronil®, Ferrosan, Sweden) was studied after administration of various parenteral and oral doses to man. After parenteral administration, the data could be fitted to a two-compartment model, but after oral dosing the distribution phase could not be separated from the elimination phase, and so an one-compartment model gave the best fit. The half-lives were about 3–4 h, except after intramuscular injection, when the half-life was about 6 h. The bioavailability of oral doses was about 60% of the intravenous injection. After the highest oral dose of 100 mg, the pharmacokinetics, expressed as AUC or Cmax, showed non-linearity, possibly due to saturation of the hepatic elimination system.

This is a preview of subscription content, log in to check access.


  1. 1.

    Christensen JA, Hernestam S, Buus-Lassen J, Sterner H (1965) Pharmacological and toxicological studies on γ-(4-methylpiperidino)-p-fluorobutyrophenone (FG5111) — a new neuroleptic agent. Acta Pharmacol Toxicol 23:109–132

    Google Scholar 

  2. 2.

    Nörgård A, Tingsgaard P, Nielsen TL (1967) Buronil ved senil konfusion og uro. (Buronil in senile confusion and anxiety). Nord Psykiatr Tidsskr 21:240–244

    Google Scholar 

  3. 3.

    Härnryd C, Bjerkenstedt L, Lindholm H, Ljungberg L (1974) En kontrollerad klinisk prövning av Buronil och haloperidol vid förvirringstillstånd hos äldre patienter. (A controlled clinical study of Buronil and haloperidol in senile confusion) Nord Psykiatr Tidsskr 28:469–472

    Google Scholar 

  4. 4.

    Haugen T (1967) Buronil®, et nytt butyrophenonderivat ved akutte psykiatriska lidelser. (Buronil, a new butyrophenone derivative in acute psychiatric illnesses) Ugeskr Laeg 129:1194–1197

    Google Scholar 

  5. 5.

    Bjerkenstedt L, Härnryd C, Grimm V, Gullberg B, Sedvall G (1978) A double blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch Psychiatr Nervenkr 226:157–172

    Google Scholar 

  6. 6.

    Carlsson C, Gullberg B, Höstery U, Christensson E (1979) A double-blind study of melperone and placebo in hospitalized chronic alcoholics in postintoxication phase. Int J Clin Pharmacol Biopharm 17:341–345

    Google Scholar 

  7. 7.

    Lindström B, Rayner S, Gullberg B, Movert R (1979) A clinical study of the effects of melperone and placebo on behavioural abnormalities in mentally retarded patients. 5th Int Congr Int Assoc Sci Study of Mental Deficiency, Jerusalem, August 1–7, 1979

  8. 8.

    Pöldinger WJ (1980) Ambulante Erfahrungen mit Melperon bei psychovegetativen Beschwerden unter kontrollierten Bedingungen. Therapiewoche 30:4862–4871

    Google Scholar 

  9. 9.

    Kirkegaard A, Kirkegaard G, Geismar L, Christensen I (1981) Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients. Arzneim Forsch 31:737–740

    Google Scholar 

  10. 10.

    Rowland M, Tucker G (1980) Symbols in Pharmacokinetics. J Pharmacokinet Biopharm 8:497–507

    Google Scholar 

  11. 11.

    Loo JCK, Riegelman S (1970) Assessment pharmacokinetic constants from postinfusion blood curves obtained after intravenous infusion. J Pharm Sci 59:53–55

    Google Scholar 

  12. 12.

    Bjerkenstedt L, Eneroth P, Härnryd C, Sedvall G (1977) Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic woman. Arch Psychiatr Nervenkr 224:281–293

    Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Borgström, L., Larsson, H. & Molander, L. Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 23, 173–176 (1982).

Download citation

Key words

  • melperone
  • neuroleptic drug
  • dose dependent kinetics
  • i.m. injection
  • i.v. injection
  • pharmacokinetics
  • oral application